---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-352229"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2026-08-14T20:09:26+00:00"
generated_at: "2026-08-14T20:18:09.424382+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences enters $150M ATM offering with Jefferies for cytisinicline funding

## Summary
- Entered Open Market Sale Agreement with Jefferies LLC for up to $150M in common stock ATM sales.
- Jefferies receives up to 3.0% commission on gross proceeds; company may suspend or terminate at any time.
- Proceeds to fund commercialization of cytisinicline and Phase 3 trial for e-cigarette cessation.
- Shares sold under existing Form S-3 registration statement filed Jan 23, 2026; no obligation to sell.

## SEC filing metadata
- accession: 0001193125-26-352229
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2026-08-14T20:09:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01, 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000119312526352229/0001193125-26-352229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000119312526352229/achv-20260814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-352229
- JSON: https://secwatch.observer/filing/0001193125-26-352229.json
- Plain text: https://secwatch.observer/filing/0001193125-26-352229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.